• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by F-star Therapeutics Inc. (Amendment)

    2/14/23 4:06:44 PM ET
    $FSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FSTX alert in real time by email
    SC 13G/A 1 tm234702d3_sc13ga.htm SCHEDULE 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Amendment No. 4)

     

    UNDER THE SECURITIES EXCHANGE ACT OF 19341

     

    F-star Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    30315R 107

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

     

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP NO. 30315R 107 13G Page 2 of 10

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ridgeback Capital Investments L.P.                       66-0677421

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
    (b) ¨ 
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    52,509

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    52,509

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    52,509

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**

     

    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.2%

    12.

    TYPE OF REPORTING PERSON**

     

    OO

     

    ** SEE INSTRUCTIONS BEFORE FILLING OUT

     

     

     

     

    CUSIP NO. 30315R 107 13G Page 3 of 10

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ridgeback Capital Investments LLC                       72-1614961

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
    (b) ¨ 
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    52,509

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    52,509

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    52,509

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**

     

    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.2%

    12.

    TYPE OF REPORTING PERSON**

     

    OO

     

    ** SEE INSTRUCTIONS BEFORE FILLING OUT

     

     

     

     

    CUSIP NO. 30315R 107 13G Page 4 of 10

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ridgeback Capital Management LLC                       42-1684320

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
    (b) ¨ 
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    52,509

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    52,509

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    52,509

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**

     

    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.2%

    12.

    TYPE OF REPORTING PERSON**

     

    OO

     

    ** SEE INSTRUCTIONS BEFORE FILLING OUT 

     

     

     

    CUSIP NO. 30315R 107 13G Page 5 of 10

     

    Item 1(a). Name of Issuer.

     

    F-star Therapeutics, Inc., f/k/a Spring Bank Pharmaceuticals, Inc. (the “Company”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices.

     

    The Company’s principal executive offices are located at Eddeva B920 Babraham Research Campus, Cambridge, CB22 3AT United Kingdom.

     

    Items 2(a). Name of Person Filing.

     

    This statement is filed on behalf of the following persons with respect to shares of common stock of the Company acquired by them (the “Shares”):

     

    (i)       Ridgeback Capital Investments L.P., Delaware limited partnership (“RCILP”), with respect to Shares beneficially owned by it;

     

    (ii)      Ridgeback Capital Investments LLC, a Delaware limited liability company (“RCI”), with respect to Shares beneficially owned by it; and

     

    (iii)     Ridgeback Capital Management LLC, a Delaware limited liability company (“RCM”), with respect to Shares beneficially owned by it.

     

    The foregoing persons are hereinafter referred to collectively as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    Item 2(b).Address of Principal Business Office or, if None, Residence.

     

    The address of the principal business office of each of the Reporting Persons is 30 Star Island Drive, Miami, FL, 33139.

     

    Item 2(c).Citizenship.

     

    RCILP is a Delaware limited partnership. RCI is a Delaware limited liability company. RCM is a Delaware limited liability company.

     

    Item 2(d).Title of Class of Securities.

     

    Common stock, $0.0001 par value per share.

     

     

     

     

    CUSIP NO. 30315R 107 13G Page 6 of 10

     

    Item 2(e).CUSIP Number.

     

    30315R 107

     

    Item 3.

     

    If this statement is filed pursuant to Rules 13d-1(b) or 13d- 2(b) or (c), check whether the person filing is a:

     

    (a) o Broker or dealer registered under Section 15 of the Act,
    (b) o Bank as defined in Section 3(a)(6) of the Act,
    (c) o Insurance Company as defined in Section 3(a)(19) of the Act,
    (d) o Investment Company registered under Section 8 of the Investment Company Act of 1940,
    (e) o Investment Adviser in accordance with Rule 13d-1 (b)(1)(ii)(E),
    (f) o Employee Benefit Plan or Endowment Fund in accordance with 13d-1 (b)(1)(ii)(F),
    (g) o Parent Holding Company or control person in accordance with Rule 13d-1 (b)(1)(ii)(G),
    (h) o Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
    (i) o Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
    (j) o A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
    (k) o

    Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _______________. 

     

    Item 4.Ownership.

     

    The percentages used herein are calculated based upon 21,981,919 shares outstanding as of September 30, 2022 as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 10, 2022. As of the close of business on December 31, 2022, the Reporting Persons beneficially owned shares of the Company’s common stock in the amounts and percentages listed below:

     

    A. Ridgeback Capital Investments L.P.
    (a) Amount beneficially owned:  52,509

     

     

     

     

    CUSIP NO. 30315R 107 13G Page 7 of 10

     

    (b) Percent of class: 0.2%
    (c) (i) Sole power to vote or direct the vote: -0-
      (ii) Shared power to vote or direct the vote:  52,509
      (iii) Sole power to dispose or direct the disposition:  -0-
      (iv) Shared power to dispose or direct the disposition:  52,509
         
    B. Ridgeback Capital Investments LLC
    (a) Amount beneficially owned:  52,509
    (b) Percent of class: 0.2%
    (c) (i) Sole power to vote or direct the vote: -0-
      (ii) Shared power to vote or direct the vote:  52,509
      (iii) Sole power to dispose or direct the disposition:  -0-
      (iv) Shared power to dispose or direct the disposition:  52,509
       
    C. Ridgeback Capital Management LP
    (a) Amount beneficially owned:  52,509
    (b) Percent of class: 0.2%
    (c) (i) Sole power to vote or direct the vote: -0-
      (ii) Shared power to vote or direct the vote:  52,509
      (iii) Sole power to dispose or direct the disposition:  -0-
      (iv) Shared power to dispose or direct the disposition:  52,509

     

    RCM and RCI do not own any Shares directly. RCI is the general partner of RCILP. Pursuant to an investment management agreement, RCM maintains investment and voting power with respect to the securities held or controlled by RCI. Wayne Holman, an individual, controls RCM. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, RCM and RCI may be deemed to own beneficially all of the Shares (constituting approximately 0.2% of the shares outstanding). Each of RCM and RCI disclaim beneficial ownership of any of the securities covered by this statement, except to the extent of any pecuniary interest therein.

     

     

     

     

    CUSIP NO. 30315R 107 13G Page 8 of 10

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.    x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    To the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the Shares which represents more than five percent of the number of outstanding shares of the Shares.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    Each of the Reporting Persons hereby makes the following certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP NO. 30315R 107 13G Page 9 of 10

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATED: February 14, 2023

     

          Ridgeback Capital Investments L.P.
           
          By: Ridgeback Capital Investments LLC,
          Its General Partner
           
        By:  /s/ Nicole Venezia
          Name:  Nicole Venezia
          Title:  General Counsel

     

          Ridgeback Capital Investments LLC
           
        By: /s/ Nicole Venezia
          Name: Nicole Venezia
          Title: General Counsel

     

          Ridgeback Capital Management LP
           
        By: /s/ Nicole Venezia
          Name: Nicole Venezia
          Title: General Counsel

     

     

     

     

    CUSIP NO. 30315R 107 13G Page 10 of 10

     

    EXHIBIT INDEX

     

    Exhibit Number Exhibit Description
    99.1 Joint Filing Agreement*

     

     

    *Previously filed.

     

     

     

    Get the next $FSTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FSTX

    DatePrice TargetRatingAnalyst
    7/15/2022$35.00 → $7.00Buy → Neutral
    H.C. Wainwright
    11/18/2021$15.00Buy
    Ladenburg Thalmann
    8/17/2021$39.00 → $35.00Outperform
    SVB Leerink
    7/8/2021$39.00Outperform
    SVB Leerink
    More analyst ratings

    $FSTX
    Financials

    Live finance-specific insights

    See more
    • invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.

      invoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has successfully completed the acquisition of F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, for an aggregate cash consideration of approximately $161 million (or $7.12 per share). F-star is currently executing Phase 2 trials in Europe and the U.S. in patients with PD-1 acquired resistant head and neck cancer, and in checkpoint inhibitor-naïve patients with non-small cell lung cancer (

      3/8/23 7:30:00 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

      Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecific Antibody TherapeuticFS118 Cleared the Futility Hurdle for the Initial Stage of the Head and Neck Acquired Resistance Cancer Trial Initiation of Combination Dosing with FS120 and KEYTRUDA® in Patients with Advanced Cancers under Supply Agreement with MSD Company Will Not be Hosting Q2 2022 Earnings Conference Call Due to the Pending Transaction with invoX Pharma CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE)

      8/11/22 8:00:00 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Four Clinical Readouts Anticipated Throughout 2022 Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American Association for Cancer Research (AACR) Annual MeetingCompany To Host Conference Call Today at 9:00 a.m. EDT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced first quarter 2022 financial results and provided a corporate update. "This year is one of the most important yea

      5/10/22 8:00:00 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.

      invoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has successfully completed the acquisition of F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, for an aggregate cash consideration of approximately $161 million (or $7.12 per share). F-star is currently executing Phase 2 trials in Europe and the U.S. in patients with PD-1 acquired resistant head and neck cancer, and in checkpoint inhibitor-naïve patients with non-small cell lung cancer (

      3/8/23 7:30:00 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Kayitalire Louis returned $178,135 worth of shares to the company (25,019 units at $7.12), closing all direct ownership in the company to satisfy tax liability

      4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

      3/9/23 9:21:33 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Forster Eliot returned $526,588 worth of shares to the company (73,959 units at $7.12), closing all direct ownership in the company (for withholding tax)

      4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

      3/9/23 9:20:14 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Klein Pamela M.

      4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

      3/9/23 9:18:56 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by F-star Therapeutics Inc.

      15-12G - F-star Therapeutics, Inc. (0001566373) (Filer)

      3/20/23 9:06:42 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by F-star Therapeutics Inc.

      EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)

      3/14/23 12:15:07 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by F-star Therapeutics Inc.

      EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)

      3/14/23 12:15:12 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • F-star Therapeutics downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded F-star Therapeutics from Buy to Neutral and set a new price target of $7.00 from $35.00 previously

      7/15/22 7:26:02 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann resumed coverage on F-star Therapeutics with a new price target

      Ladenburg Thalmann resumed coverage of F-star Therapeutics with a rating of Buy and set a new price target of $15.00

      11/18/21 9:22:57 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on F-star Therapeutics with a new price target

      SVB Leerink reiterated coverage of F-star Therapeutics with a rating of Outperform and set a new price target of $35.00 from $39.00 previously

      8/17/21 6:30:02 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by F-star Therapeutics Inc.

      SC 13G - F-star Therapeutics, Inc. (0001566373) (Subject)

      3/17/23 4:23:46 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by F-star Therapeutics Inc. (Amendment)

      SC 13G/A - F-star Therapeutics, Inc. (0001566373) (Subject)

      2/14/23 4:06:44 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by F-star Therapeutics Inc. (Amendment)

      SC 13G/A - F-star Therapeutics, Inc. (0001566373) (Subject)

      2/14/23 4:02:47 PM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • F-star Therapeutics Appoints James Sandy as Chief Development Officer

      CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that James Sandy has been appointed as Chief Development Officer, effective today. Mr. Sandy will lead the clinical development and advancement of F-star's pipeline. "We are delighted to welcome James to F-star," said Eliot Forster, CEO of F-star Therapeutics, Inc. "James brings an unparalleled depth of experience in drug development in oncology and a strong track record of enhancing and accelerating clin

      3/1/22 8:00:00 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care